Pfizer intends to provide up to two independent grants to organizations which will conduct a thorough educational needs assessment in the area of early therapy management with CDK 4/6 Inhibitors (CDK 4/6i) in mBC. For this project, early discontinuation means within the first three months of therapy.
The intent is to understand optimal ways to manage side effect profiles in the first 90 days of CDK 4/6i treatment that help patients appropriately stay on treatment and obtain maximum therapeutic benefit. These learnings will help to inform future medical education or healthcare quality improvement projects.
The needs assessment should be focused on oncologists in community cancer centers and clinics. Other multi-disciplinary healthcare professionals and care-team members should also be included. Perspectives or insights from patients may also be integrated.
Pfizer’s intent is for the results of the needs assessment to be shared with the entire medical community in order to enhance future medical education programs and close gaps in the quality of care. In addition, the results will be used to inform educational planning and future Request for Proposals.